Litcius/Paper detail

Hormesis and Endothelial Progenitor Cells

Edward J. Calabrese

2022Dose-Response18 citationsDOIOpen Access PDF

Abstract

Hormetic-biphasic dose response relationships are reported herein for human endothelial progenitor cells involving estradiol, nicotine, the anti-diabetic agent pioglitazone, resveratrol, and progesterone. In general, these studies demonstrate the capacity of these agents to enhance EPC proliferation and angiogenesis functional applications, having a focus on repairing endothelial tissue damage due to acute injury (e.g., stroke), as well as damage from chronic conditions (e.g., atherosclerosis) and normal aging processes.

Topics & Concepts

Progenitor cellHormesisAngiogenesisPioglitazoneResveratrolEndothelial progenitor cellProgenitorEndothelial stem cellNeovascularizationMedicineCell biologyCancer researchPharmacologyBiologyStem cellEndocrinologyDiabetes mellitusOxidative stressIn vitroBiochemistryType 2 diabetesAngiogenesis and VEGF in CancerEstrogen and related hormone effectsEndometrial and Cervical Cancer Treatments